anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vancomycin hydrochloride for injection can result in acute kidney injury (AKI), including acute renal failure, mainly due to interstitial nephritis or less commonly acute tubular necrosis. AKI is manifested by increasing blood urea nitrogen (BUN) and serum creatinine (Cr). The risk of AKI increases with higher vancomycin serum levels, prolonged exposure, concomitant administration of other nephrotoxic drugs, concomitant administration of piperacillin-tazobactam [see Drug Interactions (7.2)], volume depletion, pre-existing renal impairment and in critically ill patients and patients with co-morbid conditions that predispose to renal impairment.  
  
Monitor serum vancomycin concentrations and renal function in all patients receiving vancomycin hydrochloride for injection. More frequent monitoring is recommended in patients with comorbidities that predispose to impairment in renal function or are concomitantly receiving other nephrotoxic drugs, in critically ill patients, in patients with changing renal function, and in patients requiring higher therapeutic vancomycin levels. If acute kidney injury occurs, discontinue vancomycin hydrochloride for injection or reduce the dose.
<P>PROBLEM TO BE SOLVED: To provide a composition capable of lowering a blood cholesterol level, particularly a blood LDL cholesterol level without side effects.  <P>SOLUTION: The anticholesteric composition comprises a defatted product of astringent skin of a peanut. Pharmaceuticals for preventing and/or treating hypercholesterolemia and its related diseases comprise the composition. A health food comprises the composition. A manufacturing method of the composition is also provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec.
PURPOSE: To eliminate unspecific reaction caused by interference of rheumatoid factors(RF) in an immunological measuring method, by blocking an Fc part with a block reagent containing at least an antigen coupling part of an immune globulin which is specifically coupled with the Fc part of the antibody. CONSTITUTION: A block reagent eliminates interference by RF which blocks an FC part of an antibody used in an immunological measuring method, and contains at least an antigen coupling part of an immune globulin which is specifically coupled with the Fc part of the antibody. The antigen coupling part is a variable part which identifiers the antigen and can be coupled with the antigen. As an example of this block reagent, the entire immune globulin or a fragment thereof is exemplified. The immune globulin or the fragment thereof can prevent interference of the RF, and accordingly, it is preferable to have itself no part which is coupled with the RF. Although the origin and class of the immune globulin used in the block reagent are not specifically limited, the immune globulin such as a mouse or a rat can be used.
In a prospective cohort study, obese children will be recruited. After informed consent is obtained, all children will complete a standardized sleep questionnaire and a pediatric daily sleepiness scale questionnaire. All participants will undergo a complete physical examination, blood tests for lipid profile, liver enzymes, and Glucose and insulin will be obtained, and liver sonography will be performed to assess for the presence of fatty liver. Nasopharyngeal radiographs will be used to assess adenoidal size based on the method by Cohen and Konak. A standard in-laboratory, overnight polysomnography will be performed, within 2 weeks of enrollment to the study, in the sleep laboratory at Asaf Harofeh Medical Center. Children with severe obstructive sleep apnea, defined as apnea hypopnea index (AHI) \> 15 will undergo adenotonsillectomy. All children will be referred for a dietary and physical education program. The first visit with the dietician will be considered day 1 of the study. Children will than be followed monthly by a dietician. After three months of follow-up, subjects will be divided into two groups. Group 1 will include all children who had AHI \> 2 on the initial polysomnography (including children who underwent adenotonsillectomy for AHI \> 15), and group 2 will consist of children who had AHI \< 2 on the initial PSG. Children of group 2 will continue monthly dietary visits as before. Children from group 1 will undergo a second evaluation including questionnaires, laboratory blood tests, liver sonography, nasopharyngeal radiographs, and polysomnography. Children who demonstrate reduction in the AHI based on PSG will be offered to continue with dietary treatment alone. Children with no change in the AHI based on PSG will be offered to undergo adenotonsillectomy in addition to continued dietary management. All children will be followed for a total duration of six months. After six months, all children will be re-evaluated by questionnaires, blood tests, liver sonography, and nasopharyngeal radiographs. Polysomnography will be performed in all children who had an AHI \> 2 on the second PSG.
Subject recruitment will be drawn from prior participants in our Centers' research studies and the outpatient clinics. Subjects will be informed verbally and in writing of the purpose of this study. Informed consent will be obtained from all subjects who agree to participate. Subjects will be free to withdraw their consent at any time. Subject travel costs and a stipend for participation will be provided by the grant (DOD CDMRP: SC180166). Records will be kept confidential by removing the name of the subject from all data and assigning each subject a random identification number which will be recorded on all subject data sheets and linked by identifiers which are listed in a master key that is appropriately secured. An investigator or research coordinator will enroll subjects, coordinate blood laboratory studies, collect data, and coordinate the responsibilities of all study subjects. Subjects will be asked to arrive at the Center at the JJP VAMC (Room 7A-13) on the day of their appointment. A baseline EKG will be obtained to exclude participants with any EKG abnormalities. On Day 1, after obtaining subject consent, vitamin B12 will be administered transcutaneously via the wireless ION device. On Day 2, NEO (0.07 mg/kg) and GLY (0.014 mg/kg) will be administered transcutaneously via wired ION device (Dynatron iBox). On Day 3, NEO (0.07 mg/kg) and GLY (0.014 mg/kg) will be administered transcutaneously by a wireless ION device. The maximum dose of neostigmine is 10 mg or 0.07 mg/kg (whichever is less), and the maximum dose of glycopyrrolate is 2 mg or 0.014 mg/kg. All safety end points will also be collected on each day of the study.

After NEO and GLY administration, heart rate, bowel sounds, blood pressure, oxygen levels and any adverse symptoms will be recorded at times of each blood collection. Bowel sounds and evacuation time will also be recorded, if each occurs, but they are not endpoints of this protocol. The subjects will be monitored for a minimum of 120 minutes. At least two research personnel will be present during the study visit to record all data and perform the tasks required.

After the administration of each agent(s), venous blood (4 ml) will be collected into a purple-top tube (EDTA tube) at baseline, 5, 10, 20, 30, 40 60, 90, and 120 minutes. The blood will be placed in an ice bath and centrifuged to separate the formed blood cell elements from plasma. The plasma will be aliquoted in equal volume into two vials and labelled with the date, protocol number, and the subject's unique identifier and timepoint of sample collection. The samples will be placed in a -80 degrees Celsius freezer until batch shipped for assay of NEO and of GLY by mass spectroscopy in the SUNY Downstate Albany Research Laboratory by Dr. Qishan Lin.
PURPOSE: A skin external pharmaceutical composition or cosmetic composition containing marine algae extract is provided to effectively suppress cytokine synthesis with safety to human skin. CONSTITUTION: A pharmaceutical composition for treating and relieving inflammation and skin irritation contains Sargassum micracanthum and Sargassum muticum extract, their extract mixture or solvent fraction of sea algae extract. The sea algae extract is isolated using water, hydrous or anhydrous low alcohol of 104 carbon atoms or their mixture solvent. The solvent is water, ethanol, methanol, butanol, acetone, hexane, dichloromethane or ethylacetate. The pharmaceutical composition is used in the form of cream, gel, patch, spray, ointment, or lotion. The cosmetic composition is used in the form of skin softener, skin toner, astringent, lotion, milk lotion, hand cream, foundation, essence, or body lotion.
A health monitoring system and an information exchange method thereof. The health monitoring system includes a mobile terminal, a physiological condition parameter detector and a health monitoring center. The physiological condition parameter detector collects the physiological condition parameter of the user, and transmits the parameter to the mobile terminal. The mobile terminal transmits the physiological condition parameter to the health monitoring system via the communication network server. The health monitoring center diagnoses and analyses the received physiological condition parameter, and transmits the analysis result back to the mobile terminal via the communication network server. A physiological condition parameter processing module for coding and decoding the physiological condition parameter is arranged in the mobile terminal. By using communication network and internet, the health monitoring system provides a remote health monitoring between home and the health monitoring center, which facilitates the health consultation at home for the aged people and avoids the tiredness on a trip to hospital and queuing up for the register.
Mild to moderate Parkinson's disease patients, receiving no exercise intervention through the research. They will continue to receive usual and customary care for their Parkinson's disease during the 12 month period.
Vitamin compositions in the form of a dry finely-divided free-flowing solid, insoluble in water at temperatures up to 100 DEG C., comprise a fat-soluble vitamin-active composition dispersed in a carrier of retrograded amylose.  The fat-soluble vitamins are A, D, E and K, and compounds having the activity of these, including precursors thereof. Particularly mentioned are vitamin A-alcohol, -aldehyde and its phenolic complexes such as retinol quinolate, -esters such as the acetate and palmitate, and the vitamin A precursor b -carotene; the E vitamins a -tocopherol and a -tocopheryl acetate, and the oil-soluble antioxidants butylated hydroxy anisole, butylated hydroxy toluene and ethoxyquin; and natural or synthetic products having vitamin D or K activity.  Retrograded amylose is described as a water-insoluble microcrystalline substance, formed by aggregation of colloidal amylose particles in aqueous solution on ageing the solution or by other treatments; it may be colloidally dissolved in water at superatmospheric pressure and temperatures of at least 150 DEG  to 160 DEG C.  The carrier may include edible plasticisers such as sugars, gums, methyl cellulose, or gelatin.  The compositions are prepared by: (1) Preparing an aqueous colloidal solution of amylose; (2) dispersing therein the vitamin-active composition; and (3) converting the dispersion, under conditions at which the amylose retrogrades, into dry solid particles.  The amylose solution is prepared suitably from pure retrograded amylose, by either solution in water at elevated temperature and pressure, or by agitation with aqueous alkali metal hydroxide; the vitamin active composition may be dispersed therein by simple stirring or agitation.  The third step may be effected by methods wherein the dispersion is agitated with, or extruded or sprayed into, a retrogradation medium, the latter being water or a non-polar hydrocarbon, e.g. hexane when the amylose has been dissolved in superheated water, or an aqueous solution of a neutralising agent, such as an ammonium salt of a strong acid, when the amylose is dissolved in alkali.  The retrograded particles are then removed from the medium, dehydrated (e.g. by air drying) and, if required, comminuted.  Alternatively, the dispersion may be simultaneously retrograded and dried, by spray drying, or drying on a heated continuous belt, or retrograded on a chilled belt and subsequently dehydrated, and then comminuted.  The product is useful as a vitamin concentrate for addition to animal or poultry feed.
The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.
Twenty participants with lower limb loss who were referred to receive amputee rehabilitation at Hacettepe University, Faculty of Health Sciences, department of Physiotherapy and Rehabilitation, Prosthetics and Biomechanics unit, will be the subjects of this study.

Participants with lower limb loss will evaluate with the following assessment tools: Demographic datas; age, gender, height, body mass, year, side and level of limb loss will be recorded. Gait parameters (step length, variation of step length) will evaluate with Gait Trainer Biodex 2, at participant's preferred speed. To eliminate the learning effect, participants practiced at treadmill to determine appropriate gait speed. Once participants implied the preferred speed, they asked to walk at their self selected speed for 6 minutes. Data was recorded between the 2nd and 4th minutes at walk. Phantom sensation and phantom pain will be asked as existence or not. Sensorial loss will evaluate with Semmes Weinstein Monofilaments.
PURPOSE:To obtain the subject regulating agent effective in activating the antioxidation mechanism in the body formed by various intrinsic antioxidation enzymes and directly functioning as an antioxidant by using a specific aminobenzoic acid derivative as an active component. CONSTITUTION:The objective agent contains a compound of formula (R is sugar residue) or its pharmacologically allowable salt as an active component. There is no particular restriction on the sugar unit of the compound of formula provided that the sugar can be bonded to the amino group of the aminobenzoic acid and the sugar is preferably a monosaccharide (e.g., arabinoside, xyloside, glucoside, galactoside, rhamnoside and mannoside). The daily dose of the compound is preferably 1-500mg for oral administration and 0.1-100mg for parenteral administration per 1kg of the body weight. The compound has extremely low toxicity and is free from antibacterial activity. Accordingly, it can be continuously administrated over a long period without causing the disturbance of the gut flora. The agent is uninfluential to the mutagenicity, cell-mediated immunity and humoral immunity and has extremely high safety.
Aspirin has been widely used as an anti-platelet drug for the primary or secondary prevention of cardiovascular events, including ischemic heart disease and stroke. In 2016, the U.S. Preventive Services Task Force recommended initiating low-dose aspirin use for the primary prevention of cardiovascular diseases and colorectal cancer in adult aged 50 to 59 years who have a 10% or greater 10-year cardiovascular disease risk, are not at increased risk of bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. In addition, a meta-analysis reported that long-term aspirin use was associated with reduced the risk of gastrointestinal cancers including colorectal cancer, esophageal cancer, and gastric cancer. However, most studies that reported the cancer prevention effect of long-term aspirin use were conducted as a secondary analysis or subgroup analysis of primary studies investigating the aspirin use for cardiovascular disease prevention. Thus, there is a limitation that appropriate sample sizes and follow-up periods for the cancer prevention effect of aspirin were not considered.

In 2018, we reported that H. pylori treatment reduced the development of metachronous gastric cancer after endoscopic resection in early gastric cancer patients. However, metachronous gastric cancer could develop after successful H. pylori eradication with an annual incidence of 1%-3%. Therefore, we designed a multi-center, double-blind, randomized, placebo-controlled trial to evaluate whether long-term low-dose (100 mg) aspirin uses prevents gastric cancer in early gastric cancer or high-grade dysplasia patients who underwent endoscopic resection.
Experiment 6 is designed to test whether disruption of activity in left or right temporal regions (vs. vertex control) using TMS interferes with talker-specific learning. Participants will receive stimulation at all three sites (left temporal, right temporal, vertex, with order of stimulation counterbalanced across participants). The study uses a training paradigm where one talker's speech is manipulated to always have relatively short voice onset times (VOTs) for voiceless stops (e.g., /k/ in "coal") and another to have relatively long VOTs. Immediately after stimulation, listeners will undergo a training trial where they identify sounds as mapping to Talker 1 or Talker 2's voice, and to the word (e.g. "gain" vs. "cane"). At test, listeners hear two VOT variants and are asked which is more typical of that talker's speech. The dependent variable is the accuracy of reporting which variant is typical of the talker.
Tizanidine hydrochloride capsules may be prescribed with or without food. Once the formulation has been selected and the decision to take with or without food has been made, this regimen should not be altered. 

Food has complex effects on tizanidine pharmacokinetics, which differ with the different formulations. Tizanidine hydrochloride capsules and tizanidine tablets are bioequivalent to each other under fasting conditions (more than 3 hours after a meal), but not under fed conditions (within 30 minutes of a meal). These pharmacokinetic differences may result in clinically significant differences when switching administration of tablet and capsules and when switching administration between the fed or fasted state. These changes may result in increased adverse events, or delayed or more rapid onset of activity, depending upon the nature of the switch. For this reason, the prescriber should be thoroughly familiar with the changes in kinetics associated with these different conditions [see Clinical Pharmacology (12.3)]. 

The recommended starting dose is 2 mg. Because the effect of tizanidine peaks at approximately 1 to 2 hours post-dose and dissipates between 3 to 6 hours post-dose, treatment can be repeated at 6 to 8 hour intervals, as needed, to a maximum of three doses in 24 hours. 

Dosage can be gradually increased by 2 mg to 4 mg at each dose, with 1 to 4 days between dosage increases, until a satisfactory reduction of muscle tone is achieved. The total daily dose should not exceed 36 mg. Single doses greater than 16 mg have not been studied.
PROBLEM TO BE SOLVED: To convert aloeresin A to a compound having a higher commercial value.SOLUTION: This invention relates to a method for converting aloeresin A to aloesin by hydrolysis. This increases the amount of aloesin available as an extract from sap of aloe plants, and makes the extraction and the purification of aloesin more efficient at a lower cost. The commercial value of aloe sap or aloe bitter increases because the commercial value of aloesin is higher than that of aloeresin A. This invention includes a step to separate aloesin from p-coumaric acid in some cases. The hydrolysis step used in the method includes acid hydrolysis, base hydrolysis, and enzymatic hydrolysis. In the case of acid hydrolysis, its acid is a suitable organic acid or inorganic acid such as hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid. The hydrolase is an esterase, a lipase or a protease for enzymatic hydrolysis.
BACKGROUND: The key complication of myocardial infarction therapy is myocardial ischemia/reperfusion injury (MI/RI), and there is no effective treatment. The present study elucidates the mechanism of action of lncRNA KCNQ1OT1 in alleviating MI/RI and provides new perspectives and therapeutic targets for cardiac injury-related diseases.
METHODS: An ischemia/reperfusion (I/R) injury model of human adult cardiac myocytes (HACMs) was constructed, and the expression of KCNQ1OT1 and miR-377-3p was determined by RT‒qPCR. The levels of related proteins were detected by western blot analysis. Cell proliferation was detected by a CCK-8 assay, and cell apoptosis and ROS content were determined by flow cytometry. SOD and MDA expression as well as Fe2+ changes were detected by related analysis kits. The target binding relationships between lncRNA KCNQ1OT1 and miR-377-3p as well as between miR-377-3p and heme oxygenase 1 (HMOX1) were verified by a dual-luciferase reporter gene assay.
RESULTS: Myocardial ischemia‒reperfusion caused oxidative stress in HACMs, resulting in elevated ROS levels, increased Fe2+ levels, decreased cell viability, and increased LDH release (a marker of myocardial injury), and apoptosis. KCNQ1OT1 and HMOX1 were upregulated in I/R-induced myocardial injury, but the level of miR-377-3p was decreased. A dual-luciferase reporter gene assay indicated that lncRNA KCNQ1OT1 targets miR-377-3p and that miR-377-3p targets HMOX1. Inhibition of HMOX1 alleviated miR-377-3p downregulation-induced myocardial injury. Furthermore, lncRNA KCNQ1OT1 promoted the level of HMOX1 by binding to miR-377-3p and aggravated myocardial injury.
CONCLUSION: LncRNA KCNQ1OT1 aggravates ischemia‒reperfusion-induced cardiac injury via miR-377-3P/HMOX1.